Answers are grounded in this paper and cite their sources.
// Jianfeng Wang 1 , Yang Liu 1 , Naiwen Zhang 1 , Xuejie Li 1 , Peng Xin 1 , Jianbin Bi 1 and Chuize Kong 1 1 Department of Urology, The First Hospital of China Medical University, Shenyang 110001, P.R. China Correspondence to: Jianbin Bi, email: bijianbin@yahoo.com Chuize Kong, email: kongchuize_cmu@sina.com Keywords: platelet to lymphocyte ratio, urologic cancer, prognosis, meta-analysis Received: April 07, 2017 Accepted: May 23, 2017 Published: August 10, 2017 ABSTRACT The prognostic value of platelet to lymphocyte ratio (PLR) in urologic cancer does not reach a consensus. Herein, we performed the meta-analysis to determine the prognostic role of PLR in patients with urologic cancer. A literature search was performed in the PubMed, Embase, and Web of Science databases. Hazard ratios (HRs) were extracted to estimate the association between PLR and prognosis. A total of 20 articles comprising 6079 patients were included in this study. The pooled results showed that a high PLR was significantly associated with worse prognosis of overall survival (OS) in urologic cancer [HR=1.65, 95% confidence interval (CI) =1.37-1.99, P<0.01]. The result also indicated that an elevated PLR was significantly associated with poor OS in renal cancer (HR=1.88, 95% CI=1.39-2.55, P<0.01). In addition, the significant association between poor OS and elevated PLR in renal cancer was consistent regardless of treatment, cut-off value, sample size and study quality. Our result also indicated that an elevated PLR predicted shorter OS (HR=1.78, 95% CI=1.38-2.30, P<0.01) and cancer-specific survival (HR=2.02, 95% CI=1.24-3.29, P<0.01) in prostate cancer. In conclusion, an elevated PLR was a predictive indicator of poor survival in renal cancer and prostate cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: